Amylin, the Second Hormone Your Beta Cells Release With Insulin

When your beta cells release insulin after a meal, they release a second hormone in the same package, and that hormone is amylin. Insulin gets all the credit because it clears glucose that is already in the blood, but amylin works on a different part of the problem: it governs how fast glucose shows up, holds back a competing sugar-raising signal, and tells the brain the meal is over. Leave amylin out and the blood-sugar story is missing a chapter most people never read.

Key points#

• Amylin (islet amyloid polypeptide) is made in the same beta cells as insulin and released with it after meals.
• It slows the stomach's emptying, suppresses the glucose-raising hormone glucagon, and promotes a sense of fullness.
• Because it shares an origin with insulin, amylin runs low whenever beta cells fail, including in type 1 diabetes.
• A modified, non-clumping version of the peptide has made amylin biology usable in medicine and remains an active research area.

One trigger, two jobs#

Amylin is a small peptide packed into the same secretory granules as insulin. When blood glucose climbs, the granules empty and both hormones enter the bloodstream together, insulin in the larger share and amylin in the smaller. In a healthy pancreas that ratio stays fairly steady from meal to meal.

The co-packaging is the point. A single trigger, rising glucose, launches two hormones that split the work. Insulin acts downstream, directing the liver, muscle, and fat on what to do with sugar that is already circulating. Amylin acts upstream, controlling how much sugar arrives and how quickly. A useful picture: insulin is the crew unloading a delivery at the dock, while amylin is the dispatcher deciding how fast the trucks are allowed to pull in. A smooth operation needs both.

That shared origin also explains a clinical fact. Anything that damages or exhausts beta cells lowers both hormones at once. In type 1 diabetes, where the immune system destroys most beta cells, amylin is deficient right alongside insulin, a point that connects to broader work on how type 1 diabetes develops and differs across patients. In type 2 diabetes, beta cell function erodes gradually and the amylin response fades with it. So amylin is not a footnote off to the side. It belongs to the same machinery that breaks down when glucose control breaks down.

Three ways amylin flattens a post-meal spike#

Blood sugar can rise after eating through more than one route, and amylin has a distinct answer for each.

Slowing the exit from the stomach#

Amylin slows gastric emptying, the rate at which food leaves the stomach for the small intestine where sugars are absorbed. Empty the stomach more gradually and glucose trickles into the blood instead of flooding in. The total amount absorbed barely changes; the timing does. Since the sharp post-meal peak is driven mostly by speed, slowing the delivery blunts the peak on its own. Think of it as a metering valve on the inflow.

Holding glucagon down#

Glucagon comes from the pancreas's alpha cells and raises blood sugar by prompting the liver to release its stored glucose. Right after a meal you want glucagon low, because sugar is already coming in and the liver has no reason to add more. Amylin helps keep glucagon suppressed during that window. In diabetes, glucagon is often inappropriately high after eating, pushing glucose up from a second direction. A weakened amylin signal removes this brake, and the liver ends up contributing to a rise it should have sat out.

Telling the brain you are full#

Amylin also acts on satiety centers in the brainstem, where it registers the sense of having eaten enough. It trims meal size and helps bring eating to a close. This lever is slower and more behavioral than the other two, but over days and weeks it shapes how much a person eats and, in turn, body weight and overall glucose load. That appetite effect is a large part of why interest in amylin has spread well beyond the pancreas.

Line the three up and the division of labor is clear. Insulin manages the glucose already in the blood. Amylin manages the inflow: it meters delivery from the gut, blocks an unwanted top-up from the liver, and curbs how much you eat next time.

Why so few people have heard of it#

If amylin is this useful, why is it almost unknown outside metabolic research? Some of it is timing. Insulin was isolated in the 1920s and reshaped medicine within a decade. Amylin was not identified until the 1980s, and it was found the hard way, as the main ingredient of the amyloid clumps that collect in the pancreatic islets of people with type 2 diabetes. It arrived on the scene decades late and had to be understood from scratch.

Some of it is chemistry. Natural human amylin is sticky and prone to clumping, which is exactly why it forms those islet deposits in the first place. That tendency made it hard to study and harder to turn into a stable medicine. Researchers eventually engineered a modified, non-clumping form of the peptide so its effects could be delivered reliably, which opened the door to using amylin biology in treatment. It remains an active field, including approaches that pair amylin-like action with other gut-hormone signals.

And some of it is framing. Blood sugar has long been told as an insulin story, and a single-hero narrative is hard to unseat. But the glucose curve after a meal is the sum of several signals arriving in sequence, with amylin, the gut incretin hormones, glucagon, and insulin all overlapping across those few hours. Dropping amylin makes for a tidier story and a less accurate one.

None of this outranks insulin. Insulin is the hormone you cannot live without. Amylin is the fine adjustment that keeps the whole system running smoothly, and once you know it is there, the ordinary rise and fall of blood sugar around a meal starts to make more sense.